Literature DB >> 11036024

A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori.

N Tsutsui1, I Taneike, T Ohara, S Goshi, S Kojio, N Iwakura, H Matsumaru, N Wakisaka-Saito, H M Zhang, T Yamamoto.   

Abstract

The motility of Helicobacter pylori was maximum at 37 degrees C and at pH 6. A newly developed proton pump inhibitor, rabeprazole (RPZ), and its thioether derivative (RPZ-TH) markedly inhibited the motility of H. pylori. The concentrations of the drug necessary to inhibit 50% of the motility were 0.25, 16, 16, and >64 microgram/ml for RPZ-TH, RPZ, lansoprazole, and omeprazole, respectively. No such inhibitory effects were observed with H(2) blockers or anti-H. pylori agents. The motilities of Campylobacter jejuni and C. coli-but not those of Vibrio cholerae O1 and O139, Vibrio parahaemolyticus, Salmonella enterica serovar Typhimurium, and Proteus mirabilis-were also inhibited. Prolonged incubation with RPZ or RPZ-TH inhibited bacterial growth of only H. pylori, except for a turbid colony mutant. The results indicate that RPZ and RPZ-TH have a characteristic inhibitory effect against the motility of H. pylori (spiral-shaped bacteria), which is distinguished from that against bacterial growth.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036024      PMCID: PMC101604          DOI: 10.1128/AAC.44.11.3069-3073.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes.

Authors:  K A Eaton; S Suerbaum; C Josenhans; S Krakowka
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 2.  NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease.

Authors: 
Journal:  JAMA       Date:  1994-07-06       Impact factor: 56.272

3.  Adherence to human small intestines of capsulated Vibrio cholerae O139.

Authors:  T Yamamoto; M J Albert; R B Sack
Journal:  FEMS Microbiol Lett       Date:  1994-06-01       Impact factor: 2.742

4.  Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells.

Authors:  K Nagata; H Satoh; T Iwahi; T Shimoyama; T Tamura
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

5.  Comparative ultrastructural and functional studies of Helicobacter pylori and Helicobacter mustelae flagellin mutants: both flagellin subunits, FlaA and FlaB, are necessary for full motility in Helicobacter species.

Authors:  C Josenhans; A Labigne; S Suerbaum
Journal:  J Bacteriol       Date:  1995-06       Impact factor: 3.490

6.  The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism.

Authors:  C C McGowan; T L Cover; M J Blaser
Journal:  Gastroenterology       Date:  1994-11       Impact factor: 22.682

7.  The effect of pH on the growth and motility of Rhodobacter sphaeroides WS8 and the nature of the driving force of the flagellar motor.

Authors:  H L Packer; D M Harrison; R M Dixon; J P Armitage
Journal:  Biochim Biophys Acta       Date:  1994-11-01

8.  Colloidal bismuth subcitrate and omeprazole inhibit alcohol dehydrogenase mediated acetaldehyde production by Helicobacter pylori.

Authors:  R P Roine; K S Salmela; J Höök-Nikanne; T U Kosunen; M Salaspuro
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

9.  Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor.

Authors:  M Tsuchiya; L Imamura; J B Park; K Kobashi
Journal:  Biol Pharm Bull       Date:  1995-08       Impact factor: 2.233

10.  Confirmation of successful therapy of Helicobacter pylori infection: number and site of biopsies or a rapid urease test.

Authors:  H M el-Zimaity; M T al-Assi; R M Genta; D Y Graham
Journal:  Am J Gastroenterol       Date:  1995-11       Impact factor: 10.864

View more
  8 in total

Review 1.  Potent gastric acid inhibition in Helicobacter pylori eradication.

Authors:  Javier P Gisbert
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.

Authors:  Hwang-Huei Wang; Jen-Wei Chou; Kuan-Fu Liao; Zong-Yi Lin; Hsueh-Chou Lai; Chang-Hu Hsu; Chih-Bin Chen
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

Review 3.  Rabeprazole: an update of its use in acid-related disorders.

Authors:  C I Carswell; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Antiinfectives targeting enzymes and the proton motive force.

Authors:  Xinxin Feng; Wei Zhu; Lici A Schurig-Briccio; Steffen Lindert; Carolyn Shoen; Reese Hitchings; Jikun Li; Yang Wang; Noman Baig; Tianhui Zhou; Boo Kyung Kim; Dean C Crick; Michael Cynamon; J Andrew McCammon; Robert B Gennis; Eric Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

5.  Comparison of five-day Helicobacter pylori eradication regimens: rabeprazole-based and omeprazole-based regimens with and without omeprazole pretreatment.

Authors:  Kyoichi Adachi; Tomoyuki Hashimoto; Shunji Ishihara; Hirofumi Fujishiro; Shuichi Sato; Hiroshi Sato; Yuji Amano; Shuzo Hattori; Yoshikazu Kinoshita
Journal:  Curr Ther Res Clin Exp       Date:  2003-07

6.  The spatial orientation of Helicobacter pylori in the gastric mucus.

Authors:  Sören Schreiber; Manuela Konradt; Claudia Groll; Peter Scheid; Guido Hanauer; Hans-Otto Werling; Christine Josenhans; Sebastian Suerbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-25       Impact factor: 11.205

7.  Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.

Authors:  Jyh-Chin Yang; Yu-Fan Yang; Yow-Shieng Uang; Chun-Jung Lin; Teh-Hong Wang
Journal:  Br J Clin Pharmacol       Date:  2009-02-23       Impact factor: 4.335

8.  The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria.

Authors:  Agnieszka E Laudy; Ewa Kulińska; Stefan Tyski
Journal:  Molecules       Date:  2017-01-11       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.